Inflammatory Bowel Diseases

Skip Navigation LinksHome > January 2013 - Volume 19 - Issue 1 > Long-term Clinical Outcomes of Crohn's Disease and Intestina...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.22991
Original Clinical Articles

Long-term Clinical Outcomes of Crohn's Disease and Intestinal Behcet's Disease

Jung, Yoon Suk MD, MS*,†; Cheon, Jae Hee MD, PhD*; Park, Soo Jung MD, MS*; Hong, Sung Pil MD, PhD*; Kim, Tae Il MD, PhD*; Kim, Won Ho MD, PhD*

Collapse Box


Background: Crohn's disease (CD) and intestinal Behcet's disease (BD) are transmural inflammatory diseases with fluctuating courses characterized by repeated episodes of relapse and remission that often require operation or reoperation. However, no study has directly compared the long-term prognoses of these two diseases.

Methods: We reviewed the medical records of 332 patients with CD and 276 patients with intestinal BD who were regularly followed up at a single tertiary academic medical center in Korea between March 1986 and July 2010. The clinical outcomes after diagnosis and surgery were analyzed using the Kaplan—Meier method and log-rank test.

Results: There were no significant differences in the cumulative probabilities of surgery (29.4% and 36.0% vs. 31.6% and 44.4% at 5 and 10 years, respectively: P = 0.287) or admission (66.1% and 73.8% vs. 59.0% and 69.2%, P = 0.259) between CD and intestinal BD. Furthermore, no differences were observed between the two diseases for the cumulative probabilities of postoperative clinical recurrence (P = 0.724) and reoperation (P = 0.770). However, the cumulative probabilities of corticosteroid use (63.8% and 76.6% vs. 42.6% and 59.4% at 5 and 10 years, respectively: P < 0.001) and immunosuppressant use (49.1% and 65.5% vs. 27.1% and 37.7%, P < 0.001) were significantly higher in CD patients than in intestinal BD patients.

Conclusions: There were no significant differences in the long-term clinical outcomes and postoperative prognoses between CD and intestinal BD, although CD patients required corticosteroid or immunosuppressant therapy more often than intestinal BD patients.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.